文献速递类风湿关节炎其他结缔组织病

接受阿巴西普或安慰剂联合背景甲氨蝶呤治疗的类风湿关节炎患者间质性肺疾病事件发生率:一项临床试验汇编的事后汇总分析

Incidence rates of interstitial lung disease events among patients with rheumatoid arthritis treated with abatacept or placebo, with background methotrexate: a post hoc pooled analysis from a compendium of clinical trials.
PubMed 文献 · Semin Arthritis Rheum · 2025-07-16

该研究为对10项3期临床试验的回顾性汇总分析,比较阿巴西普+甲氨蝶呤(3708例,10521人年)与安慰剂+甲氨蝶呤(999例,938人年)的间质性肺疾病事件发生率。阿巴西普+甲氨蝶呤组间质性肺疾病事件发生率低于安慰剂+甲氨蝶呤组,粗发生率(95%CI)分别为0.10(0.05-0.18)与0.43(0.16-1.14),安慰剂+甲氨蝶呤相比阿巴西普+甲氨蝶呤的发生率比(95%CI)为4.49(1.23-13.42)。作者认为该结果需在前瞻性对照研究中进一步验证。

要点

  • 阿巴西普+甲氨蝶呤组间质性肺疾病事件粗发生率为0.10/100人年(95%CI 0.05-0.18)。
  • 安慰剂+甲氨蝶呤组间质性肺疾病事件粗发生率为0.43/100人年(95%CI 0.16-1.14)。
  • 安慰剂+甲氨蝶呤相比阿巴西普+甲氨蝶呤的间质性肺疾病事件发生率比为4.49(95%CI 1.23-13.42)。

核心结论

  • 在这项事后分析中,接受阿巴西普治疗的类风湿关节炎患者间质性肺疾病事件发生率低于安慰剂组,包括年龄较大、体重指数较低和无吸烟史亚组。
  • 作者认为该结果需在前瞻性对照研究中进一步验证。

研究设计与样本

  • 对10项3期临床试验的成人患者汇总安全性数据进行回顾性分析。
  • 阿巴西普+甲氨蝶呤组3708例(10521人年),安慰剂+甲氨蝶呤组999例(938人年)。
  • 间质性肺疾病事件包括提示肺炎/间质性肺疾病的急性呼吸事件。
  • 估计各组内基线人口学和疾病特征的粗发生率(每100人年)及安慰剂+甲氨蝶呤相比阿巴西普+甲氨蝶呤的发生率比。

主要发现

  • 阿巴西普+甲氨蝶呤组间质性肺疾病事件粗发生率为0.10/100人年(95%CI 0.05-0.18),安慰剂+甲氨蝶呤组为0.43/100人年(95%CI 0.16-1.14)。
  • 安慰剂+甲氨蝶呤相比阿巴西普+甲氨蝶呤的间质性肺疾病事件发生率比为4.49(95%CI 1.23-13.42)。
  • 年龄≥55岁、体重指数<30 kg/m2、无吸烟史、除甲氨蝶呤外无基线改善病情抗风湿药使用、无既往肿瘤坏死因子抑制剂使用、高DAS28-CRP、类风湿因子或抗环瓜氨酸蛋白抗体阳性且正在使用糖皮质激素的类风湿关节炎患者,接受阿巴西普+甲氨蝶呤相比安慰剂+甲氨蝶呤的间质性肺疾病事件发生率显著更低。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 本文为事后分析。
  • 作者指出该结果需在前瞻性对照研究中进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Interstitial lung disease (ILD) is a common and serious complication of rheumatoid arthritis (RA) and is associated with increased morbidity, mortality, and healthcare resource utilization. OBJECTIVE: To determine incidence rates (IRs) of ILD events in patients enrolled in clinical trials for RA who received abatacept + methotrexate (MTX) versus placebo + MTX. METHODS: We performed a retrospective analysis of pooled safety data from 10 phase 3 clinical trials of adult patients. ILD events included acute respiratory events suggestive of pneumonitis/ILD. Crude IRs per 100 person-years for baseline demographics and disease characteristics within treatment groups and IR ratios (IRRs) for placebo + MTX versus abatacept + MTX were estimated. RESULTS: Overall, 3708 (10,521 person-years) were treated with abatacept + MTX and 999 patients were treated with placebo + MTX (938 person-years). Patients treated with abatacept + MTX had a lower rate of ILD events versus patients treated with placebo + MTX: IR (95 % CI) 0.10 (0.05-0.18) versus 0.43 (0.16-1.14), respectively (IRR [95 % CI] 4.49 [1.23-13.42] for placebo + MTX vs abatacept + MTX). Patients with RA aged ≥ 55 years, body mass index < 30 kg/m2, no history of smoking, no baseline disease-modifying antirheumatic drug use other than MTX, no prior tumor necrosis factor inhibitor use, high DAS28-CRP, and rheumatoid factor or anti-citrullinated protein antibody positivity who were receiving corticosteroid(s) had a significantly lower rate of ILD events if treated with abatacept + MTX versus placebo + MTX. CONCLUSION: In this post hoc analysis, patients with RA who received abatacept had a lower rate of ILD events, including the subgroups of older age, lower body mass index, and no smoking history, compared with placebo. This warrants further investigation in prospective, controlled studies.

来源:Semin Arthritis Rheum,查看原文。版权归原作者所有。

引用

  1. Dieudé P, Sparks JA, Fischer A, et al. Incidence rates of interstitial lung disease events among patients with rheumatoid arthritis treated with abatacept or placebo, with background methotrexate: a post hoc pooled analysis from a compendium of clinical trials. Semin Arthritis Rheum. 2025. PMID: 40768904. doi:10.1016/j.semarthrit.2025.152795

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。